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The Common Cold: What Pharmacists Need to Know
Peggy Han, Pharm.D., Peggy McMillan, Pharm.D., Jeffery A. Goad, Pharm.D., BCPS
University of Southern California, School of Pharmacy

Respiratory tract infections are the most common type of infectious disease in the
United States, with the common cold being the second most frequent cause of this type of
infection.1 Children under five years of age experience four to nine episodes of upper
respiratory tract infections (URTI) per year, while children aged five to nine have an
annual frequency of four to six episodes. Incidence of URTIs in children increase as they
are exposed to more people, particularly other children in childcare facilities.2,3,4 Adults
have fewer colds, only about one to two per year. The morbidity associated with the
common cold has a major impact on the health care budget. The total costs associated
with the common cold are estimated to be approximately $24 billion dollars per year.
This includes both direct and indirect costs, such as expenditures for drugs or treatments
to relieve symptoms, lost days of work, and decreased productivity.5 Specifically, an
estimated 23 million days of work are lost each year, which is an average of almost 7
days per person in the U.S.6

Etiology

The leading cause of the common cold is the rhinovirus, which is responsible for
more than 30% of all colds and consists of over 100 serotypes. Additionally, coronavirus
is the second leading cause of colds and accounts for about one-fifth of this type of
infection.7,8 Influenza is another type of respiratory tract virus, but it is not a cause of the

common cold. Other viruses that cause cold symptoms include respiratory synctial virus
(RSV) and parainfluenza. In adults, these viruses often cause a mild self-limiting disease,
but in infants with underlying pulmonary or cardiac problems, RSV can lead to death.
Contrary to popular belief, a cold environment does not increase the risk of contracting
the common cold. Another common myth is that people with a weakened immune
system are more likely to develop a cold compared to healthy people. In fact, the
opposite may be true. Healthy people are more likely to be symptomatic from a cold
because they can mount a better cytokine response than immunocompromised
individuals.

Pathophysiology

Modes of cold virus transmission include inhalation by airborne nasal droplets,
ingestion of saliva directly or indirectly from sharing food or drink, and direct contact
with an infected individual followed by rubbing the nose or eyes. Smoking and
psychologic stress may increase susceptibility to viral upper respiratory infections. Once
infected with a cold virus, individuals can be asymptomatic for approximately 48 to 72
hours during the viral incubation period. Although individuals may be asymptomatic
during the incubation period, they may still be contagious. Inflammatory mediators,
including histamine, kinins, and interleukins, are released in the nasal passages. Host
responses to these mediators cause rhinitis, nasal secretions, nasal congestion, sneezing,
sore throat, and cough. Nasal secretions may contain virus for up to one week after the
overt symptoms of the cold are gone.9

Patient Assessment

The initial symptom of the common cold is generally a sore throat, followed by
nasal symptoms, watering eyes, sneezing, and then cough. These symptoms are usually
self-limiting, and resolve within 1-2 weeks regardless of treatment. The key to
differentiating between a cold, the flu, and a bacterial infection is to assess the symptoms.
(Table 1) For example, an abrupt onset of fever and chills without sneezing or itchy eyes
is most likely the flu.

Treatment Options

Since there is no cure for the common cold, all treatment modalities are aimed at
alleviating symptoms. In addition to any pharmacologic treatment that is instituted, nonpharmacologic measures should always be considered. These include rest and
maintaining adequate fluid intake. Humidifiers or vaporizers may also be useful to
alleviate symptoms. (Table 2)

Pharmacologic Treatment

When helping the patient select an appropriate product, the pharmacist should not
overlook the value of the patient’s prior OTC use and experience. Past product use may
be obtained from the patient profile or a quick interview with the patient.

Analgesics/Antipyretics – Fever, Sore Throat, Aches/Pains

While patients may complain of feeling feverish, high fevers are rarely seen in
patients with the common cold, and, if a fever persists, the patient should be referred to a
physician. Some patients, however, may experience slightly elevated temperatures or
mild myalgia, which may be relieved with OTC analgesics or antipyretics. While all the
OTC products are effective for these symptoms, the choice of acetaminophen, aspirin, or
an NSAID depends on the age of the patient and the presence of any co-existing diseases
or drug therapies. For example, children should not take aspirin while they have a viral
infection due to the potential for Reye’s Syndrome.
The irritated or sore throat that frequently accompanies the common cold may
result from local inflammatory mediators. Unless contraindicated, NSAIDS may be
preferred over acetaminophen or regular dose aspirin. In patients with colds,
experimental evidence suggests that acetaminophen and aspirin lower serum neutralizing
antibody titers and increase the duration of viral shedding in nasal secretions.10 In
addition, OTC lozenges, gargles, and sprays containing topical anesthetics, such as
benzocaine, dyclonine, and phenol, may be used every 3-4 hours for temporary,
symptomatic relief of a sore throat.

Decongestants – Nasal/Ocular Congestion

Decongestants are the mainstay of treatment for the common cold. They are
alpha-adrenergic agonists which constrict blood vessels throughout the body, particularly
the nasal and ocular vasculature.
Decongestants may be given orally or topically, including both intranasal and
ophthalmic preparations (Table 2). Topical decongestants are minimally absorbed,
decreasing the incidence of systemic side effects. Drainage into the stomach may occur
when excess drops are applied to the nose (nasopharynx to the stomach) or eyes
(nasolacrimal duct to the nasopharynx to the stomach), resulting in systemic absorption.
Rebound congestion (Rhinitis Medicamentosa), manifesting as increased nasal
congestion after decongestant cessation, may occur after only three days of use. This
phenomenon is more common with shorter acting topical decongestants than longer
acting agents.
Systemic decongestants, such as pseudoephedrine and phenylpropanolamine,
constrict the alpha adrenergic vascular beds and stimulate the central nervous system.
Cardiac side effects include increased blood pressure, increased heart rate, and
palpitations. Nervousness, irritability, restlessness, and insomnia may also occur.
Diseases potentially aggravated by decongestants include high blood pressure, heart
disease, diabetes mellitus, hyperthyroidism, benign prostatic hyperplasia, and angleclosure glaucoma. In addition, decongestants are contraindicated in patients taking
monoamine oxidase inhibitors (MAOIs), which may further intensify the alphaadrenergic effects of the decongestants. Therefore, when selecting a decongestant,
pharmacists should question patients about the presence of concomitant diseases and the

use of other medications. An understanding of decongestant effects on various organ
systems will aid in determining precautions and contraindications (Table 3).
The OTC decongestants are all Category C agents and, therefore, should be used
during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Additionally, lactating women should use decongestants with caution since it is unknown
how much is excreted into breast milk following topical or systemic administration.11
Topical saline drops are very safe and may be used in place of topical decongestants in
pregnancy, lactation, and in infancy.

Expectorants/Mucolytics/Antitussives - Cough

The common cold can cause either a dry, hacking cough or a productive cough
that results in the expectoration of sputum. A productive cough is the mechanism by
which the body clears the lungs and airways of unwanted materials.
Nonprescription cough products contain expectorants, such as guaifenesin, or
cough suppressants, such as dextromethorphan. Expectorants may thin sputum, increase
volume, and facilitate expulsion. Guaifenesin is thought to expel respiratory tract
secretions by reflex gastric stimulation. In 1992, the FDA warned against the use of OTC
expectorants in children under 12 years of age if there is a persistent or chronic cough,
such as occurs with asthma, or if the cough is accompanied by excessive mucus. The key
to successful use of guaifenesin is to drink plenty of fluids to lower the viscosity of the
sputum and aid in expectoration.

Antitussives, which inhibit or suppress the act of coughing, are most effective for
dry coughs. Centrally acting agents suppress the medullary centers of the brain, decrease
the sensitivity of respiratory system cough receptors, or interrupt the transmission of
cough impulses. If they are given to a patient with a productive cough, more mucus is
retained and may ultimately result in pneumonia.12 Dextromethorphan, an isomer of
levorphanol, is generally well tolerated at therapeutic dosages, however drowsiness and
GI upset may occur. While at recommended doses addiction potential is low, doses
exceeding 120 mg can result euphoria with bizarre behavior as a result of its opiate and
phencyclidine (PCP) activities.13 In addition, concomitant use with monoamine oxidase
inhibitors is not recommended due to the potential for hypertensive crisis.

Zinc

One of the most controversial and popular natural remedies for the common cold
is zinc. Zinc lozenges and lollipops are widely available in pharmacies and
supermarkets. Of ten randomized, controlled studies of zinc lozenges for the common
cold, five showed positive results and five showed negative results.14 The exact
mechanism of action of zinc is unclear, but it may inhibit viral binding to epithelial cells
in the upper respiratory tract
Past clinical trials do not consistently support the efficacy of zinc gluconate
lozenges to treat the common cold. The formulation of the lozenge, though, appears to be
important because the addition of citric acid or tartaric acid in some preparations may
actually reduce efficacy by chelating the zinc ion.15 The benefit appears to be maximal if

the lozenges are started immediately after the onset of symptoms. Common side effects
include unpleasant taste, mouth irritation and nausea. Patients should be instructed to
take one lozenge every 2 hours while awake and continue for the duration of the illness.
To minimize the incidence of nausea, the lozenges should not be taken on an empty
stomach. Additionally, citrus containing juices should be avoided within an hour of
taking a lozenge to reduce the possibility of chelation of zinc ions.15
If a patient decides to use zinc, the pharmacist should advise the patient on
conventional OTC medications that are effective for symptom management. Pediatric
use should be discouraged until more information on safety and efficacy are available.
Common OTC products containing zinc include Cold-Eeze and Zicam.

Vitamin C

The use of vitamin C to prevent or treat the common cold remains a controversial
topic. The proposed mechanism of action is that vitamin C, an antioxidant, neutralizes
the large amounts of oxidizing compounds released by neutrophils. An extensive review
of 61 trials published between 1940 and 1991 concluded that vitamin C, even in gram
doses per day, cannot prevent a cold.16 However, it has been suggested that large doses,
1-4 grams per day, may decrease the duration and severity of symptoms by 10-29%.17
The patient should be cautioned that large doses of ascorbic acid could lead to diarrhea
and renal stones.

Herbals

Herbal products have recently gained increasing interest with the public as a
remedy for the common cold. Studies of efficacy using double-blind, placebo-controlled
methods are rare. However, some of the more widely used products will be studied in the
near future under the sponsorship of the National Institutes of Health. (Table 4)

Homeopathy

Homeopathy is based on the theory similars. For example, large doses of drugs
that produce symptoms of a disease in healthy people will cure the same symptoms when
administered in extremely small amounts.18 After the many dilutions required for
potency, these products probably contain no measurable active ingredient. Although
some studies report positive findings, well-designed, clinical trials have yet to be
conducted.19 The lack of valid clinical evidence has not deterred the public from
purchasing these products to the tune of millions per year. One popular product is
oscillococcinum
Oscillococcinum is a common remedy used by practitioners of homeopathic
medicine as well as the public for the treatment of symptoms of the common cold and flu.
It contains extremely diluted constituents of autolysed duck heart and liver with literally
no “active” ingredient detectable.19,20 One placebo-controlled study conducted in France
in patients with influenza-like symptoms demonstrated a significantly greater number of

patients recovering within 48 hours after initiation of oscillococcinum compared to
placebo. However, this study was significantly flawed by multiple factors, rendering the
results useless.20

Future

Current drug therapy is aimed at ameliorating the symptoms of the cold, not eliminating
the causative virus. Pleconaril is a new investigational antiviral drug with activity against
picornoviruses, including rhinoviruses and enteroviruses, a cause of viral meningitis.21
Initial trials of Pleconaril versus the common cold did not demonstrate a dramatic
decrease in cold symptoms, but subsequent trials may show otherwise.

Conclusion

Despite the numerous OTC products available for symptomatic treatment of the
common cold, a definitive cure remains to be discovered. Supportive care remains the
mainstay of therapy. Therefore, as pharmacists, it is important that we assess each
patient individually, taking into account other disease states and current drug therapy, as
we target our counseling and recommendations to the individual’s specific symptoms.
(Table 5)
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Table 1 Influenza vs. Common Cold vs. Bacterial Infection
Characteristic
Presentation
Onset
Fever
Differential
symptoms

Fatigue,
weakness, &
exhaustion
Duration
Complications

Influenza
Generalized
Sudden
High (>100F)
Headache
Chills
Muscle pains
Nonproductive Cough
Sore throat
Anorexia
Extreme

Common Cold
Local-nose & throat
Gradual
Mild
Sneezing
Nasal congestion
Sore throat
Productive cough

Bacterial
Systemic
Gradual-sudden
High (>100F)
Chills
Chest pain
Productive cough
Tachycardia
Tachypnea

Mild

Extreme

1-5 days high fever; 13 weeks symptoms
Pneumonia; bronchitis

1 week; rapid
recovery
Earache

variable
Sepsis

Table 2 Symptomatic OTC Treatment of the Common Cold
Symptom
Nasal congestion and discharge

Treatment
Decongestants
Systemic
Ephedrine
Phenylephrine
Phenylpropanolamine
Pseudoephedrine
Inhalers
Desoxyephedrine
Propylhexedrine
Topical (duration)
Short Acting (4-6 hours)
Ephedrine
Epinephrine
Naphazoline
Phenylephrine
Tetrahydrazoline
Intermediate Acting (8-10 hours)
Xylometazoline
Long Acting
Oxymetazoline

Cough

Sore throat

Feverishness and headache
Adapted from reference 23

Ophthalmic
Epinephrine
Naphazoline
Oxymetazoline
Phenylephrine
Tetrahydrazoline
Hydration
Antitussives
Expectorants
Cool mist/steam vapors
Saline gargles
Local anesthetics
Systemic analgesics
Systemic analgesics

Table 3 Adverse Effects and Potential Contraindications of Decongestants
Target Symptoms

Systemic Effects

Adverse Effects

Blood vessels

Constricts

Hypertension

Heart

Stimulates

Tachycardia

Eye

Constricts radial
muscle
Constricts bladder
sphincter
Stimulates

Increase intraocular
pressure
Obstructs urinary
flow
Hyperthyroidism
Hyperglycemia
Excitability

Genitourinary
tract
Exocrine glands
Central nervous
system

Stimulates

Potential
Contraindications
Hypertensive
patients
MAOI use within
past 2 weeks
Arrhythmia
Cardiovascular
disease
Glaucoma
BPH
Hyperthyroidism
Diabetes
Seizures

Table 4 Herbal Products
Herb
Echinacea

Use
Supportive therapy for
colds and chronic infections
of the respiratory tract;
immunostimulant

Ephedra (Ma Huang)

Bronchial asthma (produces
bronchodilation,
vasoconstriction, and
reductions in bronchial
edema)

Goldenseal

Antimicrobial, astringent,
and antihemorrhagic
activity in the treatment of
mucosal inflammation
Expectorant, antitussive

Horehound

Adapted from reference 22

Clinical Considerations
 Cross sensitivity in
patients allergic to
sunflower seeds
 Caution in patients with
autoimmune disease,
AIDS, or leukemia
because of T-cell and
macrophage stimulation
 Not recommended for
chronic use
 Avoid in patients with
cardiac conditions,
HTN, diabetes, or
thyroid disease
 Side effects:
nervousness, insomnia,
palpitation
 Avoid concomitant use
with decongestants,
weight control products
 Absolute
Contraindicated in
pregnancy


FDA declared
ineffective as a cough
suppressant and
expectorant

Table 5 Patient Counseling Tips







Select medications that treat only the symptoms you have.
Don’t take medicines longer or in higher doses than the label recommends. If
symptoms persist, see a physician.
If the label says use two teaspoons, use a measuring spoon, or a dosing cup marked in
teaspoons, or an oral syringe, instead of a common kitchen spoon.
Find out if the patient has other medical conditions (diabetes, hypertension,
hyperthyroidism) or is currently taking any prescription or nonprescription
medications that should be considered in selecting a product.
Determine what products have been tried and the outcome of prior therapy.
Select a product that is most convenient for the patient to take to enhance compliance.

